← Back to Search

A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors

N/A
Waitlist Available
Led By Elizabeth Jewell, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to collect information on the effects of treatment for gestational trophoblastic disease (GTD). We plan to use the findings from this study to better understand GTD survivors' health and quality of life. We would like to know more about the health, quality of life and pregnancies of women treated for GTD. This information will be used to try and improve the treatments for women who have this disease.

Eligible Conditions
  • Cervical Dysplasia
  • Gestational Trophoblastic Disease
  • Gestational Trophoblastic Tumor
  • Uterine Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: 2Experimental Treatment1 Intervention
30 patients survived GTD post treatment 6 - 10+ years.
Group II: 1Experimental Treatment1 Intervention
30 patients survived GTD post treatment for 0 - 5 years.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
questionnaire
2019
N/A
~6450

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,977 Previous Clinical Trials
599,678 Total Patients Enrolled
Elizabeth Jewell, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
318 Total Patients Enrolled
~3 spots leftby Dec 2025